<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Whitehawk Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc</link>
<description>Latest news and press releases for Whitehawk Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sun, 19 Apr 2026 22:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/whitehawk-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d86278dffbe2df1229ca.webp</url>
<title>Whitehawk Therapeutics, Inc.</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc</link>
</image>
<item>
<title>Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-presents-comprehensive-preclinical-data-highlighting-its-next-generation-adc-portfolio-at-the-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-presents-comprehensive-preclinical-data-highlighting-its-next-generation-adc-portfolio-at-the-aacr-2026</guid>
<pubDate>Sun, 19 Apr 2026 22:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of new preclinical data across its ADC portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA.</description>
</item>
<item>
<title>Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-jones-trading-post-aacr-fireside-chat-series</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-jones-trading-post-aacr-fireside-chat-series</guid>
<pubDate>Thu, 16 Apr 2026 20:05:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the Jones Trading Post-AACR Fireside Chat Series on Thursday, April 23, 2026, at 3 PM ET.</description>
</item>
<item>
<title>Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-presents-real-world-analysis-confirming-muc16-as-a-highly-expressed-clinically-relevant-target-for-gynecologic-cancers-at-sgo-2026</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-presents-real-world-analysis-confirming-muc16-as-a-highly-expressed-clinically-relevant-target-for-gynecologic-cancers-at-sgo-2026</guid>
<pubDate>Fri, 10 Apr 2026 11:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented three posters from a real-world analysis supporting the therapeutic potential of targeting mucin 16 (MUC16) with a next-generation ADC for the treatment of ovarian and endometrial cancers at the Society of Gynecologic Oncology (SGO) 2026 Annual Meetin</description>
</item>
<item>
<title>Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-highlight-its-next-generation-adc-portfolio-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-highlight-its-next-generation-adc-portfolio-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>MORRISTOWN, N.J., March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced</description>
</item>
<item>
<title>Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-highlights-7</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-highlights-7</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16-targeted ADC HWK-016HWK-206 on track for planned IND</description>
</item>
<item>
<title>Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Wed, 18 Feb 2026 13:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 8:40 AM EST.</description>
</item>
<item>
<title>Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-advances-to-clinical-stage-with-ind-clearance-for-hwk-007-and-announces-ind-submission-for-hwk-016</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-advances-to-clinical-stage-with-ind-clearance-for-hwk-007-and-announces-ind-submission-for-hwk-016</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for HWK-007, its PTK7-targeted ADC. Whitehawk's Phase 1 trial for HWK-007 is now actively recruiting and will initially evaluate activity in lu</description>
</item>
<item>
<title>Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-appoints-margaret-dugan-md-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-appoints-margaret-dugan-md-as-chief-medical-officer</guid>
<pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the appointment of Margaret Dugan, MD, as Chief Medical Officer (CMO). Dr. Dugan brings more than 30 years of global oncology drug development experience, with extensive expertise in early-stage clinical development and regulatory strategy.</description>
</item>
<item>
<title>Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference</guid>
<pubDate>Wed, 26 Nov 2025 13:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City, NY on December 3, 2025, at 12:30 PM ET.</description>
</item>
<item>
<title>Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-present-at-jefferies-global-healthcare-conference-in-london</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-present-at-jefferies-global-healthcare-conference-in-london</guid>
<pubDate>Tue, 11 Nov 2025 13:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 11:30 AM GMT.</description>
</item>
<item>
<title>Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-reports-third-quarter-2025-financial-results-and-recent-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-reports-third-quarter-2025-financial-results-and-recent-highlights</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the third quarter ended September 30, 2025, and provided recent corporate progress.</description>
</item>
<item>
<title>Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-presents-real-world-analysis-confirming-ptk7-as-a-broadly-expressed-clinically-relevant-target-across-solid-tumors-at-aacr-nci-eortc</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-presents-real-world-analysis-confirming-ptk7-as-a-broadly-expressed-clinically-relevant-target-across-solid-tumors-at-aacr-nci-eortc</guid>
<pubDate>Fri, 24 Oct 2025 16:30:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented data from a real-world analysis of Protein Tyrosine Kinase 7 (PTK7) at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. As part of a collaboration between Whitehawk and Tempus AI, the analysis evaluated real-world data</description>
</item>
<item>
<title>Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/tempus-announces-collaboration-with-whitehawk-therapeutics-to-advance-biomarker-driven-oncology-research</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/tempus-announces-collaboration-with-whitehawk-therapeutics-to-advance-biomarker-driven-oncology-research</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a</description>
</item>
<item>
<title>Whitehawk Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat during the following upcoming investor conferences in New York City, NY:</description>
</item>
<item>
<title>Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-reports-second-quarter-2025-financial-results-and-recent-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-reports-second-quarter-2025-financial-results-and-recent-highlights</guid>
<pubDate>Thu, 07 Aug 2025 12:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, today announced financial results for the second quarter ended June 30, 2025, and provided recent corporate progress.</description>
</item>
<item>
<title>Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-the-btig-virtual-biotechnology-conference</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-the-btig-virtual-biotechnology-conference</guid>
<pubDate>Tue, 22 Jul 2025 12:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's management will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025.</description>
</item>
<item>
<title>Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-hc-wainwright-hcwhome-series</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-hc-wainwright-hcwhome-series</guid>
<pubDate>Thu, 19 Jun 2025 12:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that Dave Lennon, PhD, President and CEO, and David Dornan, PhD, Chief Scientific Officer, will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, June 26, 2025, at 10 AM ET.</description>
</item>
<item>
<title>Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-present-at-the-jefferies-2025-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-present-at-the-jefferies-2025-global-healthcare-conference</guid>
<pubDate>Wed, 28 May 2025 12:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today its presentation at the Jefferies 2025 Global Healthcare Conference, taking place June 3-5, 2025, in New York City, NY. Dave Lennon, PhD, President and CEO, will present a company overview on Wednesday, June 4, 2025, from 2:00-2:30 PM ET.</description>
</item>
<item>
<title>Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-the-td-cowen-6th-annual-oncology-innovation-summit</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-therapeutics-to-participate-in-the-td-cowen-6th-annual-oncology-innovation-summit</guid>
<pubDate>Wed, 21 May 2025 12:00:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on May 28, 2025, at 2:30 PM ET.</description>
</item>
<item>
<title>Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-reports-first-quarter-2025-financial-results-and-recent-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/whitehawk-therapeutics-inc/news/whitehawk-reports-first-quarter-2025-financial-results-and-recent-highlights</guid>
<pubDate>Thu, 08 May 2025 20:05:00 GMT</pubDate>
<description>Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, today announced financial results for the first quarter ended March 31, 2025, and provided recent corporate progress.</description>
</item>
</channel>
</rss>